Abstract:Background/Aims: Radiation therapy is an important and effective modality for the treatment of non-small cell lung cancer (NSCLC). MicroRNAs (miRNAs) are crucial post-transcriptional regulators that are involved in numerous important biologic processes. However, their potential involvement in radiation sensitivity remains unknown. Materials: We performed integrated analysis of miRNA expression in NSCLC using The Cancer Genome Atlas datasets. miR-99a was found to be significantly upregulated in cancer tissue and regulated cell survival. Cell culture was used to assess the role of miR-99a in radiation sensitivity. We then used flow cytometry to examine the effects of miR-99a on the cell cycle and apoptosis in cells exposed to radiation. To identify gene targets of miR-99a, a bioinformatics approach was adopted, and the findings of this analysis were verified using luciferase reporter assays. Finally, an in vivo study was conducted to examine the effect of miR-99a on tumor volume in an NSCLC mouse model undergoing radiation therapy. Results: miR-99a was significantly upregulated in radiation-sensitive A549 cells compared with radiation-resistant A549 cells. miR-99a overexpression was shown to enhance radiosensitivity, while inhibition of miR-99a resulted in radioresistance of NSCLC cell lines in vitro and in vivo. In addition, by bioinformatics software analysis and luciferase assays, mammalian target of rapamycin (mTOR) was identified as a direct target of miR-99a. Furthermore, AZD2014, an inhibitor of mTOR, enhanced radiosensitivity and apoptosis in NSCLC cell lines, while mTOR overexpression resulted in radioresistance and cell survival from miR-99a-induced cell apoptosis. Moreover, miR-99a overexpression further increased the efficacy of radiation therapy in an NSCLC xenograft mouse model, and miR-99a and mTOR expression was significantly inversely correlated. Conclusions: Altogether, these data suggested miR-99a functions as a tumor suppressor that has a critical role in regulating radiosensitivity of NSCLC by targeting the mTOR signaling pathway.

MicroRNAs targeted mTOR as therapeutic agents to improve radiotherapy outcome

miRNAs in radiotherapy resistance of cancer; a comprehensive review

Targeting MicroRNAs in Prostate Cancer Radiotherapy

Inhibition of Mtor Enhances Radiosensitivity of Lung Cancer Cells and Protects Normal Lung Cells Against Radiation

Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy

Emerging Role of MicroRNAs in Mtor Signaling

Microbeam Radiotherapy—A Novel Therapeutic Approach to Overcome Radioresistance and Enhance Anti-Tumour Response in Melanoma

Exploiting the therapeutic potential of microRNAs in human cancer

miRNA: A Promising Therapeutic Target in Cancer

Targeting Mtor Network in Colorectal Cancer Therapy

MiR-99a Enhances the Radiation Sensitivity of Non-Small Cell Lung Cancer by Targeting mTOR

Radiation therapy for triple-negative breast cancer: emerging role of microRNAs as biomarkers and radiosensitivity modifiers. A systematic review

Targeting Mtor for Cancer Therapy

Progress on the Relationship Between Mirna and Lung Cancer in Radiosensitivity

Radiation-induced Tumor Immune Microenvironments and Potential Targets for Combination Therapy

Radiotherapy-activated tumor immune microenvironment: Realizing radiotherapy-immunity combination therapy strategies

The emerging role of microRNA in regulating the mTOR signaling pathway in immune and inflammatory responses

Mir-410 Induces Both Epithelial–mesenchymal Transition and Radioresistance Through Activation of the PI3K/mTOR Pathway in Non-Small Cell Lung Cancer

Regulatory mechanisms and clinical perspectives of miRNA in tumor radiosensitivity

Targeted Inhibition of Mammalian Target of Rapamycin (mtor) Enhances Radiosensitivity in Pancreatic Carcinoma Cells.

Tissue-specific and exosomal miRNAs in lung cancer radiotherapy: from regulatory mechanisms to clinical implications